|
US9266891B2
(en)
|
2012-11-16 |
2016-02-23 |
Boehringer Ingelheim International Gmbh |
Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
|
|
US9765039B2
(en)
|
2012-11-21 |
2017-09-19 |
Zenith Epigenetics Ltd. |
Biaryl derivatives as bromodomain inhibitors
|
|
US9073878B2
(en)
|
2012-11-21 |
2015-07-07 |
Zenith Epigenetics Corp. |
Cyclic amines as bromodomain inhibitors
|
|
JP2016507496A
(ja)
|
2012-12-21 |
2016-03-10 |
ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． |
ブロモドメイン阻害剤としての新規複素環式化合物
|
|
EA035469B1
(ru)
|
2013-03-15 |
2020-06-22 |
Инсайт Холдингс Корпорейшн |
Трициклические гетероциклы как ингибиторы белков бэт
|
|
EA027139B1
(ru)
*
|
2013-04-26 |
2017-06-30 |
Бейджин, Лтд. |
Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
|
|
KR102307566B1
(ko)
|
2013-06-21 |
2021-10-05 |
제니쓰 에피제네틱스 리미티드 |
신규한 바이사이클릭 브로모도메인 억제제
|
|
CN105473581B
(zh)
|
2013-06-21 |
2019-04-23 |
齐尼思表观遗传学有限公司 |
作为溴结构域抑制剂的新取代的双环化合物
|
|
EP3019502B1
(en)
|
2013-07-08 |
2017-05-17 |
Incyte Holdings Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
CA2919948C
(en)
|
2013-07-31 |
2020-07-21 |
Zenith Epigenetics Corp. |
Novel quinazolinones as bromodomain inhibitors
|
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
|
US9315501B2
(en)
|
2013-11-26 |
2016-04-19 |
Incyte Corporation |
Bicyclic heterocycles as BET protein inhibitors
|
|
US9309246B2
(en)
|
2013-12-19 |
2016-04-12 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
SMT202000133T1
(it)
|
2014-04-23 |
2020-05-08 |
Incyte Corp |
1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
|
|
US9902702B2
(en)
*
|
2014-07-15 |
2018-02-27 |
Bristol-Myers Squibb Company |
Spirocycloheptanes as inhibitors of rock
|
|
JP6599979B2
(ja)
|
2014-09-15 |
2019-10-30 |
インサイト・コーポレイション |
Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
|
|
TWI716367B
(zh)
|
2014-10-31 |
2021-01-21 |
麻省理工學院 |
用於常間回文重複序列叢集（ｃｒｉｓｐｒ）之大量平行組合性基因學
|
|
US10179125B2
(en)
|
2014-12-01 |
2019-01-15 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
HK1245246A1
(zh)
|
2014-12-01 |
2018-08-24 |
恒翼生物医药科技(上海)有限公司 |
作为溴域抑制剂的取代吡啶酮
|
|
WO2016092375A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Corp. |
Substituted heterocycles as bromodomain inhibitors
|
|
CN107406438B
(zh)
|
2014-12-17 |
2021-05-14 |
恒翼生物医药科技(上海)有限公司 |
溴结构域的抑制剂
|
|
KR20180012861A
(ko)
*
|
2015-06-16 |
2018-02-06 |
오리온 코포레이션 |
브로모도메인 억제제로서의 스피로[사이클로부탄-1,3'-인돌린]-2'-온 유도체
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
WO2017075377A1
(en)
|
2015-10-29 |
2017-05-04 |
Incyte Corporation |
Amorphous solid form of a bet protein inhibitor
|
|
CN109715625B
(zh)
|
2016-06-20 |
2022-04-19 |
因赛特公司 |
Bet抑制剂的结晶固体形式
|
|
WO2018109271A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Orion Corporation |
New bromodomain inhibitors
|
|
CN107739370B
(zh)
*
|
2017-10-26 |
2021-03-30 |
中国药科大学 |
吡咯酮类brd4蛋白抑制剂的制备方法以及用途
|
|
CN109928979B
(zh)
*
|
2017-12-15 |
2021-08-06 |
四川科伦博泰生物医药股份有限公司 |
吲哚酮类衍生物及其制备方法和用途
|
|
CN108383771A
(zh)
*
|
2018-01-08 |
2018-08-10 |
华东师范大学 |
手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用
|
|
ES3053198T3
(en)
|
2018-08-27 |
2026-01-20 |
Arcus Biosciences Inc |
Cd73 inhibitors
|
|
WO2020102216A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Substituted heterocyclic derivatives as pi3k inhibitors
|
|
US11161838B2
(en)
|
2018-11-13 |
2021-11-02 |
Incyte Corporation |
Heterocyclic derivatives as PI3K inhibitors
|
|
WO2020102198A1
(en)
|
2018-11-13 |
2020-05-22 |
Incyte Corporation |
Heterocyclic derivatives as pi3k inhibitors
|
|
JP7636646B2
(ja)
|
2019-04-09 |
2025-02-27 |
オプナ バイオ ソシエテ アノニム |
Ｅｐ３００またはｃｂｐの調節のための縮合アジンおよびその適応
|
|
CN114502534A
(zh)
|
2019-09-30 |
2022-05-13 |
协和麒麟株式会社 |
Bet降解剂
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
EP3912625A1
(en)
|
2020-05-20 |
2021-11-24 |
Kaerus Bioscience Limited |
Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
EP4580618A2
(en)
*
|
2022-08-30 |
2025-07-09 |
Pannex Therapeutics Inc. |
Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated
|
|
WO2025233532A1
(en)
|
2024-05-10 |
2025-11-13 |
Les Laboratoires Servier |
Maxi-k potassium channel openers and therapeutic applications thereof
|